Correlations Between Inflammatory Biomarkers and Activity in Inflammatory Bowel Diseases

Abstract

There is an increasing interest in non-invasive methods to assess gut inflammation. The data regarding the correlations between inflammatory markers and activity of inflammatory bowel disease (IBD) are still controversial. In the last years faecal calprotectin became the most widely used biomarker in diagnosis and monitoring the IBD activity. We prospectively studied the correlation between the serological inflammatory markers (platelets, erythrocyte sedimentation rate - ESR, fibrinogen, C Reactive Protein -CRP, ferritin, albumin), faecal calprotectin and severity of IBD in a tertiary referral centre in North-East Romania. Our study demonstrated that is a good correlation between serologic inflammatory markers (platelets, fibrinogen and ferritin, not ESR and albumin) and severity of IBD. CRP is a good marker in Crohn�s disease (CD) but not in ulcerative colitis (UC). Faecal calprotectin (FC) is the best inflammatory biomarker which correlates with activity both in UC and CD. Inflammatory biomarkers, especially FC are an important tool to evaluate patients with IBD.

Correlation of Circulating Cathelcidin Level and Inflammatory Bowel Disease Activity

“…LL37 was found in many types of cells, including neutrophils that were mostly housed in granules. The results agreed with Mihai et al (2018) in USA who reported that platelets were inflammatory biomarker and IBD associated with thrombocytosis.…”

“…But, Vermeire et al (2006) disagreed with the present CRP point as they found that CRP was not a specific IBD marker and only an objective marker of correlated with disease activity in CD but rare with UC. Also, Mihai et al (2018) Romania reported that despite CRP was considered a powerful serum marker co-or-dinated with inflammatory activity, there were patients with a normal CRP and increased disease activity, as well as with a raised CRP and inactive disease in 196 (48 with CD &148 with UC) IBD patients at the Institute of Gastroenterology and Hepatology. The disease severity of flare in CD was determined by the CDAI score and UC by using Mayo (UCDAI) scoring system.…”

Use of helminth therapy for management of ulcerative colitis and Crohn's disease: a systematic review

“…A limitation within some of the studies themselves is the way in which efficacy was measured. There is some evidence suggesting that the CDAI, UCDAI and the Mayo score may not be the most reliable way of tracking disease activity in relation to the assessment of treatment and that they don't always correlate well with endoscopic assessment, inflammation and mucosal healing (Filik et al ., 2006 ; Morris et al ., 2013 ; Mihai et al ., 2018 ). Whilst all are historically validated tools, they represent more of a view of the patient's subjective well-being than the actual level of mucosal inflammation seen in the disease (Mihai et al ., 2018 ).…”

Impact of Therapy with L-Thyroxine on the Evolution of Arterial and Aortic Stiffness in Female Patients with Overt and Subclinical Hypothyroidism

“…Taking into account that age, obesity and high blood pressure (BP) are well-known predictors of AS and DD, we excluded all subjects aged over fifty-four years, with body mass index (BMI) over 30, or with BP over 139/89 mmHg. We excluded all participants with diabetes mellitus, overt CV diseases or chronic renal diseases, dyslipidaemia (low density lipoprotein (LDL) cholesterol over 135 mg/dL), women who were postmenopausal or had history of smoking that could explain the presence of subclinical atherosclerosis [17,18]. We followed the evolution of these patients under therapy with L-thyroxine and evaluated AS, the aortic elasticity, LVH and DD initially and after 6 months of therapy when all patients reached the euthyroid state.…”